Weekly Care Review: What Its GLP-1 Documents Establish—and What They Don’t

A low advertised price can answer a shopping question without answering an evidence question. Weekly Care promotes compounded Semaglutide+ starting at $89 per month and compounded Tirzepatide+ starting at $99 per month, alongside online evaluation, included provider visits and expedited shipping. Those are concrete commercial claims. They do not establish how well its particular preparations work, which formulation a patient would receive or what the complete financial commitment would be. This review separates the service Weekly Care documents from the clinical conclusions those documents cannot support.

The public pages consulted on October 19, 2026, describe a U.S. platform connecting patients with independent medical professionals and partner pharmacies. Weekly Care’s terms explicitly say the company does not itself provide healthcare. That division matters throughout the experience: a clinician decides whether to prescribe, a pharmacy dispenses, and Weekly Care handles platform and administrative functions. The documentation is relatively specific about cancellation and shipping procedures, but less complete about clinical follow-up and the conditions behind its starting prices. No treatment was purchased or independently tested for this review.

At a glance

Advertised starting prices: Compounded Semaglutide+ starts at $89/month and compounded Tirzepatide+ at $99/month, with the same advertised price at every dose. The pages do not explain the commitment or supply quantity required for those rates.
Sources: [8]
Platform, not treating provider: Weekly Care’s terms say it is not a healthcare provider; independent professionals determine whether a prescription is appropriate.
Sources: [6] [8]
Compounded injectable offerings: Both product pages describe subcutaneous administration. The site acknowledges that compounded medications are not FDA approved or evaluated by FDA for safety, effectiveness or quality.
Sources: [10] [11]
Coverage and payment: Weekly Care advertises service in all 50 states and Washington, D.C., subject to state-dependent options. It operates on a self-pay basis and does not bill insurance.
Sources: [8]
Important order boundary: The cancellation policy permits a refund after consultation if the order has not reached the pharmacy, but ordinarily bars cancellation and refund once the prescription is transmitted.
Sources: [5]

Start with the product evidence, not the ingredient name

Weekly Care’s two advertised offerings are compounded Semaglutide+ and compounded Tirzepatide+. Their product pages describe injections under the skin, rather than tablets or another route. However, the consulted documentation does not identify what the “+” adds or establish the exact formulation a particular patient would receive. That is a meaningful gap for an evidence-focused comparison. A familiar ingredient name is not a complete product description; the assigned preparation, dispensing pharmacy and accompanying instructions remain matters to confirm before proceeding.

Weekly Care explicitly acknowledges that compounded medications are not FDA approved. FDA explains that these preparations do not undergo its premarket review for safety, effectiveness and quality, and recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not prove clinical inequivalence, but it also does not supply missing product-specific evidence. Our guide to approved medicines and compounded preparations explains this distinction. Nothing in the consulted record establishes FDA approval of Weekly Care or its compounded offerings.

Sources: [8] [10] [11] [1]

Clinical trials are context, not a Weekly Care performance report

The clinical literature helps explain interest in these medicines, but it must be kept separate from this platform’s claims. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide in a comparable broad weight-management population, also excluding diabetes. Neither was a study of Weekly Care, its pharmacy partners or its compounded preparations. Their results cannot establish this company’s treatment outcomes, the performance of an unspecified added ingredient or an individual patient’s likely response.

The practical question is not whether an ingredient has appeared in a successful trial, but how closely the actual treatment matches the evidence being invoked. Route, formulation, population, duration and monitoring all matter to that interpretation. The consulted Weekly Care documentation does not provide provider-specific outcome data that would bridge those questions. Nor should trial averages become a ranking of telehealth businesses. Our explanation of why a clinical trial is not a company performance report offers a framework for reading such claims without dismissing the underlying research.

Sources: [3] [4] [10] [11]

Who evaluates, prescribes and keeps the medical record?

Weekly Care LLC owns and operates the website, according to its privacy policy. Its terms distinguish the platform from the professionals delivering healthcare. The homepage identifies David Wasef, MD, as Wasef Health’s founder and medical director and says Weekly Care partners with Wasef Health for access to licensed medical providers. Intake begins with a medical questionnaire. An independent professional reviews the information and may prescribe if treatment is appropriate; completing intake does not guarantee medication. These are documented descriptions of the arrangement, not independent verification of credentials or licenses.

The terms limit services to adults 18 or older located in the United States, while allowing additional age restrictions for certain products. Weekly Care’s tirzepatide page also says not to use its compounded product with a personal or family history of medullary thyroid carcinoma, MEN 2, a serious allergy to tirzepatide or any formulation ingredient, or during pregnancy, planned pregnancy or breastfeeding. The terms also require separate electronic telehealth consent and acknowledge that remote care is not always a substitute for an in-person evaluation. Medical records created during care are maintained by the treating provider, not Weekly Care; requests for copies must go directly to that provider. Before enrolling, a reader can reasonably ask who will conduct the consultation, how to contact that professional and how any necessary in-person care would be coordinated.

Sources: [7] [6] [8] [11]

The prices are documented; the complete purchase is not

The homepage’s starting prices are clear enough to report, but not complete enough to treat as personalized quotes. Compounded Semaglutide+ starts at $89 per month; compounded Tirzepatide+ starts at $99 per month. Weekly Care advertises the same price at every dose. The consulted pages do not explain the qualifying commitment, any upfront collection or the supply quantity attached to those rates. Separately, the cancellation policy discusses six-month plans without establishing their total price, billing schedule or dispensing schedule. A plan’s duration does not itself establish a six-month medication supply or a mandatory minimum commitment.

Weekly Care says prescribed medication, provider visits, supplies, two-day shipping and ongoing support are included, with no separate monthly membership or provider fees. Those inclusions should be read alongside the pharmacy-channel exception below. The platform does not bill insurance; possible HSA or FSA reimbursement depends on the individual plan. Required laboratory testing and any associated charges are not specified in the consulted documentation. A useful prepayment request is therefore an itemized quote showing the initial charge, later charges, billing interval, assigned product and any services outside the advertised package.

What the advertised package establishes—and what still needs confirmation
Item	Documented position	Question still to resolve
Compounded Semaglutide+	Starting at $89/month; same advertised price at every dose	Required commitment, exact formulation and supply quantity
Compounded Tirzepatide+	Starting at $99/month; same advertised price at every dose	Required commitment, exact formulation and supply quantity
Included services	Medication, provider visits, supplies and two-day shipping advertised	Required testing and any separate laboratory charges
Six-month plans	Addressed in the cancellation policy	Total price, collection schedule and dispensing schedule
Outside pharmacy	Patient obtains medication and pays that pharmacy directly	How that choice affects the platform’s package charge

Sources: [8] [6] [5]

Pharmacy choice changes both responsibility and cost

Weekly Care says it works with licensed 503A compounding pharmacies and names Hallandale Pharmacy and VialsRx as examples. Those are the company’s statements, not license checks performed for this review. The consulted documentation does not establish which pharmacy or formulation would serve a particular patient. The homepage advertises availability in all 50 states and Washington, D.C., while warning that medications, formulations and fulfillment options can vary by state. Broad geographic availability therefore should not be read as a promise that every advertised option is available everywhere.

The terms say certain prescriptions may be filled through the network or at a pharmacy of the patient’s choice. Within the network, prescriptions may be transferred among participating pharmacies, with patient notification. If a patient selects an outside pharmacy, Weekly Care sends the prescription there, but the patient must obtain the medication and pay that pharmacy directly. This is a material limitation on the apparent all-in package. The documents do not explain how an outside fill changes the platform charge, so that financial question should be resolved separately rather than assuming medication remains included.

Sources: [8] [6]

Ongoing care needs more definition than seven-day support

The homepage promises continued care from the partner medical team and Weekly Care administrative support seven days a week for orders, shipments and related issues. Its privacy policy says communications with healthcare professionals take place exclusively through the HIPAA-governed patient portal. These statements identify separate communication routes, but do not establish seven-day clinician availability. The consulted pages do not specify medical response times, a routine consultation schedule, required testing, clinical renewal intervals or Spanish-language clinical access. Administrative availability should not be substituted for a documented follow-up plan.

Weekly Care’s semaglutide page asks patients to provide a full medical history and a complete list of prescriptions, nonprescription medicines, vitamins and supplements. Its tirzepatide page warns that oral contraceptives may be less effective, particularly when treatment starts and after each dose increase, and asks patients using birth control pills to discuss this with their provider before starting. The general importance of that discussion is supported by NIDDK, which describes medication selection as a balance of benefits, side effects, health conditions, other medicines, family history and cost. The missing operational detail is how that assessment continues after the first order. Our guide to clinical follow-up beyond renewal notices explains why tolerance and response require attention beyond successful payment collection.

Sources: [8] [7] [10] [2] [11]

Renewal cancellation and order refunds have different boundaries

The terms say certain purchases require automatically renewing subscriptions, with charging intervals disclosed during checkout, and allow requests to pause or cancel. The cancellation policy directs patients to email help@weekly.care. Once cancellation is confirmed, the plan remains active through the current billing cycle and further renewals stop; unused time does not receive a partial or prorated refund. For a six-month plan with at least three months remaining, a refund is not automatic and rests with Weekly Care’s discretion. That language makes cancellation a forward-looking billing action, not a general money-back promise.

Order status creates another boundary. After consultation, cancellation for a refund is allowed before the medication order is submitted to the pharmacy. Once the prescription is transmitted, the policy ordinarily bars cancellation and refund. A clinician’s finding of medical ineligibility results in a full refund, while confirmed duplicate charges or billing errors also qualify. Delays or communication concerns do not automatically qualify. Refund requests are reviewed within two to four business days; approved refunds are returned to the original payment method within five to ten business days, with additional bank-posting time possible.

Sources: [6] [5]

Shipping speed and medication condition are separate questions

The homepage promotes provider review in one day and delivery in one to two days, but labels these estimates dependent on clinical review, approval, pharmacy processing, availability and shipping conditions. The operating policy instead says medications generally ship within two to four business days following provider approval and pharmacy preparation. Dispatch is not arrival. Fulfillment occurs Monday through Friday, excluding federal holidays, using expedited service such as UPS 2nd Day Air. Tracking is emailed when an order ships and may take up to 24 hours to activate. These details make the promotional timeline unsuitable as a guaranteed intake-to-door promise.

Damaged packages must be reported within 24 hours, with a photograph and retained packaging; verified cases receive replacement or refund. A shipment marked delivered but missing also requires notification within 24 hours and documentation, with a police report potentially required for suspected theft. The policy does not grant remedies solely for melted ice packs unless Weekly Care or the pharmacy determines integrity was compromised. Separately, FDA advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated and contacting the provider or pharmacy. Our guide to delivery and cold-chain claims distinguishes that safety advice from reimbursement rules.

Sources: [8] [5] [1]

Questions & answers

Can I actually enroll for $89 or $99 without a longer commitment?

The consulted pages do not establish that. Weekly Care advertises compounded Semaglutide+ starting at $89 per month and compounded Tirzepatide+ starting at $99 per month, but does not explain the commitment, upfront payment or quantity necessary to obtain those rates. Its policy separately mentions six-month plans. Ask for the complete checkout terms rather than assuming either a month-to-month option or mandatory six-month prepayment.

Sources: [8] [5]

Does Weekly Care guarantee a prescription after I complete intake?

No. Its documented process requires an independent professional to review the medical intake and determine whether treatment is appropriate. A prescription may follow, but it is not guaranteed. The cancellation policy says an order is canceled with a full refund when a licensed healthcare professional determines the patient is not medically eligible. The public documentation does not establish a distinct Weekly Care BMI admission rule for its compounded program.

Sources: [8] [5]

Can I choose my pharmacy instead of using a partner?

The terms permit an outside pharmacy for certain prescriptions. Weekly Care sends the prescription to the selected pharmacy, but the patient must arrange to obtain it and pay that pharmacy directly. Do not assume the advertised package covers that outside purchase. Within the partner network, prescriptions may be filled by or transferred between participating pharmacies, with notification. Confirm the assigned pharmacy, formulation and financial consequences before selecting a channel.

Sources: [6]

Does seven-day support mean a clinician will answer every day?

That is not established. Weekly Care advertises seven-day administrative support for shipments, orders and other concerns, alongside ongoing care from its partner medical team. Its privacy policy places healthcare communications in the patient portal. The consulted documents do not specify clinician hours or response-time commitments. Ask separately about routine clinical questions, time-sensitive concerns and scheduled reassessments rather than treating administrative support hours as a medical availability guarantee.

Sources: [8] [7]

What should I do if a delivery arrives warm?

FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Weekly Care’s financial policy separately says melted ice packs alone do not establish eligibility for replacement or refund unless it or the pharmacy determines medication integrity was compromised. Document the condition promptly. Its damaged-package procedure requires reporting within 24 hours, a clear photo and retention of packaging.

Sources: [1] [5]

How private are the website and patient communications?

The privacy policy distinguishes provider communications through a HIPAA-governed portal from general website activity. It says identifiers and online activity may be shared with advertising and analytics partners, while protected health information governed by its HIPAA notice is excluded from advertising or marketing disclosures. A California notice separately says the company does not sell personal information or share it for cross-context behavioral advertising. Those statements merit clarification, but the documents alone do not establish a legal contradiction.

Sources: [7] [9]

Our assessment

Weekly Care documents a recognizable access model: independent clinical review, compounded injectable offerings, partner-pharmacy fulfillment and self-pay packages with advertised inclusions. Its explicit nonapproval disclosure and detailed order, refund and shipping policies give readers useful boundaries to examine. The weaker points are the unexplained conditions behind starting prices, unspecified “+” formulations, incomplete follow-up arrangements and absence of provider-specific outcome evidence in the consulted record. None of those gaps proves poor care, but clinical trials of semaglutide or tirzepatide cannot fill them. Before paying, obtain the exact product and pharmacy, complete billing schedule, clinical contact plan and applicable cancellation stage in writing. That information would make comparison more meaningful than either a low monthly headline or an ingredient-level efficacy claim.

Visit Weekly Care’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Weekly Care Review: What Its GLP-1 Documents Establish—and What They Don’t

At a glance

01Start with the product evidence, not the ingredient name

02Clinical trials are context, not a Weekly Care performance report

03Who evaluates, prescribes and keeps the medical record?

04The prices are documented; the complete purchase is not

05Pharmacy choice changes both responsibility and cost

06Ongoing care needs more definition than seven-day support

07Renewal cancellation and order refunds have different boundaries

08Shipping speed and medication condition are separate questions